|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality.
Description: Considering healing and/or reducing symptoms and severity of initial presentationMeasure: Illness development Time: 7 days
Description: Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive careMeasure: Reduction of need ICU admission Time: 14 days
Description: Preventing patient from dyingMeasure: Reduction of mortality rate Time: 30 days
Description: potential need of reducing or augmenting dosesMeasure: Optimyzing doses of drugs used in the clinical trial Time: 14 days
Description: Outcome of adverse effects to one or more drugs used in the clinical trialMeasure: Adverse effects Time: 14 days